BioRender-Icon

VEGFR3

VEGFR3 - Editable icon of VEGFR3
[{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c53/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c53/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c52/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c52/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c51/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c51/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c50/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c50/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c4f/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c4f/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c4e/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c4e/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c4d/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c4d/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c4c/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c4c/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c4b/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c4b/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c4a/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c4a/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c49/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c49/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c48/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c48/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c47/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c47/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c46/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c46/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c45/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c45/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c44/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c44/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c43/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c43/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c42/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c42/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c41/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c41/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c40/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c40/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c3f/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c3f/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c3e/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c3e/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c3d/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c3d/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c3c/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c3c/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c3b/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c3b/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c3a/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c3a/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c39/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c39/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c38/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c38/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c37/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c37/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c36/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c36/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c35/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c35/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c34/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c34/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c33/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c33/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c32/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c32/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c31/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c31/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c30/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c30/60510f73ebe3a10026503c2e.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/6051101cebe3a10026503c2f/60510f73ebe3a10026503c2e.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/6051101cebe3a10026503c2f/60510f73ebe3a10026503c2e.png"}]
Dieses Icon verwenden – Kostenlos
Für die Registrierung ist keine Kreditkarte erforderlich.

Dieses Icon ist in BioRender vollständig bearbeitbar

  • Fügen Sie Text, Formen und weitere Icons hinzu
  • Durchsuchen Sie über 50.000 wissenschaftlich korrekte Icons
  • Jedes Icon, jede Linie und jedes Label lässt sich umfärben und neu anordnen
  • Exportieren oder teilen für jeden Anwendungszweck
Scientist Avatars

Schließen Sie sich über 4 Millionen Wissenschaftlern an, die bereits publikationsreife Abbildungen erstellen

Vom Icon zur fertigen Abbildung – in wenigen Minuten

  • Suche aus über 50.000 wissenschaftlich korrekten, von Experten begutachteten Icons
  • Anpassen mit Beschriftungen, Formen und zusätzlichen Icons – alles ist vollständig bearbeitbar
  • Exportieren oder teilen Sie Ihre Abbildungen mit Mitarbeitern
    ‍

Nicht ganz das richtige Icon? Entdecken Sie mehr.

Durchsuchen Sie über 50.000 Icons aus mehr als 30 lebenswissenschaftlichen Fachbereichen.

search icon
arrow-right
Schlagwörter
VEGF receptor,VEGFR3,vascular endothelial growth factor 3,vascular permeability factor 3,VPF3,VEGF,membrane bound,mbVEGFR,soluble,sVEGFR,monomer,growth factor,platelet-derived growth factor,cystine-knot,vasculogenesis,vascular endothelium,mitogenesis,cell migration,microvascular permeability,tyrosine kinase,transphosphorylation,immunoglobulin-like domains,VEGFR3
Mehr anzeigen

Versuchen Sie es mit einem Synonym oder registrieren Sie sich, um ein Icon über die App anzufordern.

Bildtypen

VEGFR3 icon JPEG

VEGFR3 icon PNG

VEGFR3 icon SVG

VEGFR3 icon GIF

Häufig gestellte Fragen zu BioRender-Icons

How are scientists using the VEGFR3 icon in their work?

BioRender users often use the VEGFR3 icon in posters, grant applications, educational materials, and graphical abstracts. It’s especially useful for projects involving Proteins.

Kann ich dieses Icon in einer BioRender-Abbildung oder wissenschaftlichen Illustration verwenden?

Yes, the VEGFR3 is fully integrated into BioRender’s drag-and-drop platform. You can easily add it to any scientific figure, workflow, or poster, whether you’re building from scratch or starting with a BioRender template.

Is the VEGFR3 icon customizable in BioRender?

Most icons in BioRender, including the VEGFR3 icon, are customizable. You can adjust icon size, colors, and positioning, and add custom labels to tailor the design to your specific research context.

Can I export figures that include the VEGFR3 icon for publication or presentations?

Yes, figures containing the VEGFR3 icon can be exported in multiple formats, including PNG, JPG, PDF, and SVG. High-resolution and vector exports are available on paid plans, making them ideal for journals, slide decks, and print materials.

How do I cite BioRender if I use this icon?

Unlock publication permissions with a paid plan, and include 'Created with BioRender.com' in your figure legend, or cite BioRender directly per your journal's guidelines.

Is the VEGFR3 icon used in BioRender templates or poster layouts?

Many BioRender templates include icons like the VEGFR3 icon — especially those focused on Proteins. You can search BioRender’s template library or add this icon manually to any canvas.

Was ist BioRender?

BioRender is a web‑based software that helps you create scientific figures in minutes. Use this VEGFR3 icon along with our library of more than 30,000 life science icons.

Dieses Icon in BioRender verwenden

Erstellen Sie noch heute professionelle wissenschaftliche Abbildungen
antibody elements3D Phospholipid illustration

Suchen Sie nach wissenschaftlichen Inhalten?

Durchsuchen Sie über 50.000 Icons und Vorlagen, die von Fachkollegen geprüft, einfach zu verwenden und kostenlos sind.

Finden Sie jetzt das Passende
x icon